Enhancing the antidepressant effects of scopolamine through mGlu2 receptor antagonism as an emerging approach for treating depression

Conventional antidepressants remain not effective enough to treat depression, with only 30–40% of patients achieving full remission. This has intensified the call for a deeper understanding of depression’s biological mechanisms, moving beyond the traditional monoaminergic hypothesis. The cholinergic hypothesis, first proposed in the 1970s, has gained renewed interest due to the rapid antidepressant effects of scopolamine, a muscarinic receptor antagonist. Despite its potential, scopolamine’s side effects hinder clinical use. Recent research highlights dysregulation of glutamatergic neurotransmission in depression, and targeting metabotropic glutamate (mGlu) receptors presents a novel therapeutic strategy. Evidence suggests that mGlu 2 receptors play a critical role in the rapid antidepressant effect, and mGlu 2 receptor antagonists possess antidepressant-like potential in animal models of depression. Importantly, mGlu 2 antagonists such as LY341495 or the mGlu 2 negative allosteric modulator VU6001966, when coadministered with scopolamine, enhance scopolamine’s antidepressant efficacy while reducing cognitive side effects. Data indicate that ligands of other mGlu receptor subtypes, including group III mGlu receptors, may also enhance the therapeutic effects of scopolamine while avoiding undesirable effects. This review study underscores the urgent need for innovative approaches to depression treatment, emphasizing the importance of mGlu 2 as a promising target for future therapeutic development, especially as co-treatment with low doses of scopolamine. The mechanism related to the potentiation of the antidepressant effect of scopolamine by VU6001966, including activation of AMPA receptors and BDNF–TrkB signaling, is also discussed.

Authors

Institutions

Publication Details

Journal
Pharmacological Reports
Published
2026-11-16
DOI
https://doi.org/10.1007/s43440-026-00928-5
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Enhancing the antidepressant effects of scopolamine through mGlu2 receptor antagonism as an emerging approach for treating depression

Agnieszka Pałucha-Poniewiera, Andrzej Pilc, Yana Babii
Pharmacological Reports
Treatment of Major Depression
article

Enhancing the antidepressant effects of scopolamine through mGlu2 receptor antagonism as an emerging approach for treating depression

Agnieszka Pałucha-Poniewiera, Andrzej Pilc, Yana Babii
article en

Abstract

Conventional antidepressants remain not effective enough to treat depression, with only 30–40% of patients achieving full remission. This has intensified the call for a deeper understanding of depression’s biological mechanisms, moving beyond the traditional monoaminergic hypothesis. The cholinergic hypothesis, first proposed in the 1970s, has gained renewed interest due to the rapid antidepressant effects of scopolamine, a muscarinic receptor antagonist. Despite its potential, scopolamine’s side effects hinder clinical use. Recent research highlights dysregulation of glutamatergic neurotransmission in depression, and targeting metabotropic glutamate (mGlu) receptors presents a novel therapeutic strategy. Evidence suggests that mGlu 2 receptors play a critical role in the rapid antidepressant effect, and mGlu 2 receptor antagonists possess antidepressant-like potential in animal models of depression. Importantly, mGlu 2 antagonists such as LY341495 or the mGlu 2 negative allosteric modulator VU6001966, when coadministered with scopolamine, enhance scopolamine’s antidepressant efficacy while reducing cognitive side effects. Data indicate that ligands of other mGlu receptor subtypes, including group III mGlu receptors, may also enhance the therapeutic effects of scopolamine while avoiding undesirable effects. This review study underscores the urgent need for innovative approaches to depression treatment, emphasizing the importance of mGlu 2 as a promising target for future therapeutic development, especially as co-treatment with low doses of scopolamine. The mechanism related to the potentiation of the antidepressant effect of scopolamine by VU6001966, including activation of AMPA receptors and BDNF–TrkB signaling, is also discussed.

Pharmacological Reports
Maj Institute of Pharmacology (PL), Polish Academy of Sciences (PL)
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon